Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Macugen

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Vascular endothelial growth factor B (VEGF-B) was discovered a long time ago. However, its role in hyperglycemia- and VEGF-A… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2011
2011
Purpose: To examine if the sequential treatment of Avastin and Macugen is safe and more efficient than the mono-therapies in a… Expand
Is this relevant?
2008
2008
The 2'-fluoro/2'-O-methyl modified RNA aptamer Macugen is a potent inhibitor of the angiogenic regulatory protein, VEGF165… Expand
  • table 2
Is this relevant?
2008
2008
AIMS This prospective, open label, non-comparative, observational case series evaluates 6-month results of Pegaptanib Sodium… Expand
Is this relevant?
2008
2008
BACKGROUND VEGF signalling is deregulated in diabetic retinopathy. Therefore, VEGF inhibitors like the modified RNA… Expand
Is this relevant?
Highly Cited
2007
Highly Cited
2007
AimTo compare the antiproliferative and cytotoxic properties of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab… Expand
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Review
2007
Review
2007
Both clinical and preclinical findings have implicated vascular endothelial growth factor (VEGF) in the pathophysiology of… Expand
Is this relevant?
Highly Cited
2006
Highly Cited
2006
OBJECTIVE To study effects of intravitreal pegaptanib (Macugen) on retinal neovascularization. DESIGN Retrospective analysis of… Expand
Is this relevant?
Review
2006
Review
2006
Repeated Macugen intravitreal injections, well tolerated and safe when performed according to protocol, is the first successful… Expand
Is this relevant?
Review
2006
Review
2006
Macugen (pegaptanib sodium), manufactured by Eyetech Pharmaceuticals, Inc., and Pfizer, Inc., is the first treatment approved by… Expand
Is this relevant?